Journal
CELLULAR SIGNALLING
Volume 16, Issue 6, Pages 693-701Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2003.11.002
Keywords
activin; human hepatocarcinoma cells; cyclin-dependent kinase inhibitor
Categories
Ask authors/readers for more resources
In this report, we examined the role of activin in the regulation of cell growth inhibition of human hepatocarcinoma cells. Using RNase protection assay for various cell cycle regulators and Western blotting experiments, we show that activin treatment of HepG2 cells leads to increased gene expression of the cyclin-dependent kinase inhibitor (CDK1) p15(INK4B). Furthermore, transient co-transfection studies of the P15(INK4B) promoter/luciferase construct performed in HepG2 cells demonstrates that activin induction of the p15(INK4B) promoter is mediated through the Smad pathway. p15(INK4B) gene promoter mapping analysis revealed a 66-bp region within the proximal domain of the promoter, which contains a consensus site for the transcription factor Sp1, as critical for mediating the activin effect on p15(INK4B) gene expression. Finally, gel mobility shift experiments, using the Sp1 consensus site, revealed increased DNA binding of Sp1 in response to activin treatment of HepG2 cells, further confirming the involvement of Sp1 in activin-mediated p15(INK4B) gene promoter activation. Together, our data indicates an important role for the cyclin-dependent kinase inhibitor p15(INK4B), in activin-induced cell cycle arrest in liver cells. (C) 2003 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available